Target
$81.26 → $80.96
Current stock research snapshot · 7/31/26 26 days old
BSXBoston Scientific
Investment conviction●●○○○2 of 5 · current snapshot
Research target$80.96Current stock price target
Investment thesis statusNEEDS_MORE_DATALast reviewed 7/31/26
Market cap$68.43BSnapshot value · 7/31/26
Research history
See all BSX changes ↗What changed
Target
$81.25 → $81.26
Healthspan taxonomy seed — see taxonomy_path
Boston Scientific Q2 2026 earnings; Farapulse (PFA) adoption in AFib; WATCHMAN market share expansion; TAVR growth
Thesis weakens if WATCHMAN deceleration continues (referral softness makes CV mix dependent on FARAPULSE alone), or EP competitors (Abbott Volt, FARAWAVE Ultra ~2027) close the clinical gap so PFA switching costs prove lower than modeled. (vault 2026-08)
Bullish — Medical devices sector value play with 31-38% upside models cited Aug 24 2026 [X search Aug 2026]
Snapshot · 7/31/26🟢 Lean-Bull · ins+$9.9M(9buy👥)→7.9M · 13F 15+/10-×0.5 · short↑0.27
Snapshot · 7/31/26Timestamped research update
Deep research update
504 words · Updated Aug 9, 2026 · 2 sources
Research in development: this latest 504-word update is published for context while it is expanded toward the 1,000-word editorial standard.
Boston Scientific is a global medical-device company focused here on minimally invasive cardiovascular and interventional systems: electrophysiology (FARAPULSE PFA), coronary therapies (AGENT drug-coated balloon), WATCHMAN left atrial appendage closure, and other catheter-based procedure platforms.
Q2 2026 net sales were $5.442B (+7.5% reported, +7.0% operational/organic), gross profit was $3.848B, operating income was $1.178B, gross margin was 70.7%, operating margin was 21.6%, cash and equivalents were $539M, and total debt was $12.624B (actual leverage 2.02x vs 4.0x covenant max).
The moat is procedural adoption, not hardware novelty: once an EP lab standardizes on FARAPULSE/PFA and related workflows, switching requires physician retraining, proctoring, inventory changes, and protocol revalidation. That procedural inertia is what lets Boston Scientific monetize a recurring consumables stream while also defending share in high-value AF ablation.
- Q2 2026 net sales $5.442B versus $5.061B a year ago; Cardiovascular revenue grew 8.3% and MedSurg 5.9% [SEC 10-Q filed 2026-08-03; SEC 8-K EX-99.1 2026-07-29]
- The 10-Q says the reported net sales growth was primarily driven by coronary therapies and Electrophysiology, led by the FARAPULSE Pulsed Field Ablation System [SEC 10-Q]
- Boston Scientific said growth was also impacted by increased competition in Electrophysiology and a deceleration of certain WATCHMAN procedures — a real reminder that the moat is franchise-specific, not universal [SEC 10-Q]
- Gross profit $3.848B on $5.442B of sales implies 70.7% gross margin; operating income $1.178B implies 21.6% operating margin, showing the device mix still converts into strong economics [SEC 10-Q]
- Heart Rhythm 2026 late-breaking data: the AVANT GUARD study of FARAPULSE PFA met all safety and effectiveness endpoints and showed statistical superiority versus anti-arrhythmic drugs; ELEVATE-PF also supported the next-generation FARAFLEX catheter [SEC 8-K EX-99.1]
The bottleneck is the procedure platform and physician workflow. Publicly visible switching frictions are (1) EP lab capital and device setup, (2) training/proctoring, (3) institutional credentialing and protocol changes, and (4) the loss of accumulated operator comfort if the lab moves away from the incumbent workflow. A practical switching-cost model for a mid-size EP lab is roughly $0.35M-$1.0M: assessment and vendor review ($25k-$75k), parallel-run/proctoring and dual inventory ($100k-$250k), retraining and protocol revalidation ($75k-$200k), and throughput drag during conversion ($150k-$500k). That is not impossible to pay, but it is enough to slow adoption and preserve incumbency when the incumbent keeps improving outcomes.
- WATCHMAN deceleration is a live warning that not every franchise is sticky; if procedural referrals continue to soften, the Cardiovascular mix could become more dependent on FARAPULSE alone.
- Increased competition in Electrophysiology means PFA is becoming a battleground, not a monopoly; if competitors close the clinical gap, switching costs may prove lower than the model implies.
- How much of the Q2 Cardiovascular growth is FARAPULSE versus AGENT DCB, and how durable is each through H2 2026?
- Does the WATCHMAN slowdown reflect temporary referral noise or a longer-term share pressure problem?
INTACT
Primary and supporting material
Sources
2 sources preserved from the latest qualified research update.